- With far more women filing for claims than expected (249,000 not including foreign claims), the global settlement fund for silicon breast-implant lawsuits, which was geared up to pay between $140,000 and $1.4 billion in damages per claimant, is likely only to be able to pay out sums of 5% of the amounts initially announced. The plaintiffs are seeking to convince the defendants, who include Dow Corning, Bristol-Myers Squibb and Baxter International, to put up an additional $1 billion to pay for the illness-related claims.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze